GLP-1 Drugs, Pregnancy, and Contraception: What the Labels and Evidence Say

Research log — verified against the FDA prescribing information for semaglutide and tirzepatide, plus published pharmacology and clinical commentary (searched July 2026). GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and the GLP-1/GIP dual agonist tirzepatide (Mounjaro, Zepbound) have moved from diabetes clinics into mainstream weight management. That shift has surfaced two reproductive-health questions the labels address directly: these drugs are not recommended in pregnancy, and they can interact with fertility and with contraception in ways many users do not expect. This is an educational summary, not medical advice.

The labels: not recommended in pregnancy

Both drug classes carry consistent pregnancy language. The manufacturers' prescribing information states these medicines should not be used during pregnancy and should be discontinued when pregnancy is recognized. The stated rationale is twofold: intentional weight loss offers no benefit to a pregnant patient, and animal reproductive-toxicity studies showed embryofetal harm — including reduced fetal growth and structural abnormalities in some studies — at clinically relevant exposures. Human pregnancy data remain limited and largely observational, so the animal signals plus the absence of adequate human safety data drive the "not recommended" stance rather than proof of harm in people.

For anyone actively planning a pregnancy, the labels go further than "stop when you find out." Because these are long-acting drugs, guidance is to stop before conception and allow a washout. Semaglutide has a half-life of roughly one week, so the Wegovy label instructs discontinuing at least 2 months before a planned pregnancy to allow near-complete clearance. Tirzepatide has a shorter half-life of about 5 days; preconception guidance commonly cited is roughly 1 month of washout, though clinicians sometimes advise a longer margin. These are label- and pharmacology-based rules of thumb, not one-size-fits-all prescriptions — the right timeline is a conversation with your own prescriber.

You can review the regulatory framing for each compound in our library: semaglutide and tirzepatide, and see how approval status is categorized on our FDA status page.

The "Ozempic babies" phenomenon

Alongside weight loss, clinicians began noticing unexpected pregnancies among GLP-1 users — informally dubbed "Ozempic babies." The most-supported explanation is straightforward: weight loss can restore ovulation. Obesity and conditions such as polycystic ovary syndrome (PCOS) are associated with irregular or absent ovulation, and even modest weight reduction — well within what these drugs commonly produce — can restore menstrual regularity and fertility. Improvements in insulin sensitivity and related hormonal changes are thought to contribute. In other words, a person who assumed they could not easily conceive may suddenly be far more fertile, sometimes before they realize it.

The National Geographic reporting and fertility-clinic commentary reviewed here frame this as a plausible, biologically coherent trend rather than a proven "baby boom" — the population-level data are still early. But at the individual level the practical implication is clear: restored fertility plus a drug that is not recommended in pregnancy is a combination worth planning around.

The contraception wrinkle — especially with tirzepatide

The second mechanism is about birth control itself. GLP-1 drugs slow gastric emptying, which can reduce how much of an oral medication is absorbed. This matters most for oral hormonal contraceptives (the pill).

Here the two drugs differ, and the labels reflect it. Tirzepatide's prescribing information includes a specific warning: it may reduce the absorption of oral hormonal contraceptives. In the label's drug-interaction study, peak levels of the contraceptive hormones fell substantially (ethinyl estradiol peak concentration dropped around 59%, with total exposure down roughly 20%). Because of this, the tirzepatide label advises users of oral contraceptives to either switch to a non-oral method (such as an IUD, implant, injection, or patch) or add a barrier method (such as condoms) for 4 weeks after starting and for 4 weeks after each dose increase. The effect is largest at initiation and after dose escalations, when gastric emptying is most delayed, and it diminishes over time.

Semaglutide's labels do not carry the same requirement. Drug-interaction studies did not show a clinically relevant reduction in oral-contraceptive exposure, likely because its effect on gastric emptying attenuates with continued use. That said, the underlying biology is shared, so some clinicians still counsel caution during titration.

Putting it together

Three practical themes emerge from the sources reviewed:

None of this is a reason for alarm; these are manageable, label-documented considerations. The recurring theme is timing: the drugs are long-acting, fertility can shift quickly, and oral birth control can be temporarily less reliable. If any of these apply to you, the right move is a specific plan made with a licensed clinician who knows your history — not a rule pulled from a blog.

PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.